Results 281 to 290 of about 99,858 (332)

Downregulation of O‐GlcNAcylation enhances etoposide‐induced p53‐mediated apoptosis in HepG2 human liver cancer cells

open access: yesFEBS Open Bio, Volume 15, Issue 7, Page 1176-1188, July 2025.
Etoposide, a topoisomerase II inhibitor, reduces O‐GlcNAcylation in HepG2 liver cancer cells. Further inhibition of O‐GlcNAc transferase by OSMI‐1 enhanced etoposide‐induced apoptosis, lowering the IC50 for viability and increasing the EC50 for cytotoxicity.
Jaehoon Lee   +5 more
wiley   +1 more source

β‐Glucuronidase‐Expressing Lactobacillus reuteri Triggers Irinotecan Enterotoxicity Through Depleting the Regenerative Epithelial Stem/Progenitor Pool

open access: yesAdvanced Science, Volume 12, Issue 26, July 10, 2025.
XLP mitigated CPT11 mucositis by suppressing GUS‐expressing microbes, notably L. reuteri, and diminishing bacterial GUS activity, consequently reducing SN38 accumulation to protect the intestinal epithelium. This preservation of the mucosal stem cell niche enabled rapid regeneration of secretory lineages such as mucin‐producing goblet cells, which ...
Bei Yue   +15 more
wiley   +1 more source

Preoperative donor urinary UDP-Glc as an independent risk factor for delayed graft function. [PDF]

open access: yesFront Immunol
Ma M   +9 more
europepmc   +1 more source

Sortilin‐Mediated Rapid, Precise and Sustained Degradation of Membrane Proteins via mRNA‐Encoded Lysosome‐Targeting Chimera

open access: yesAdvanced Science, Volume 12, Issue 25, July 3, 2025.
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang   +8 more
wiley   +1 more source

Uridine-sensitized screening identifies genes and metabolic regulators of nucleotide synthesis

open access: yes
Strefeler A   +7 more
europepmc   +1 more source

HDAC6 and USP9X Control Glutamine Metabolism by Stabilizing GS to Promote Glioblastoma Tumorigenesis

open access: yesAdvanced Science, Volume 12, Issue 25, July 3, 2025.
Glioblastoma (GBM) growth relies on glutamine synthetase (GS), which is stabilized by histone deacetylase 6 (HDAC6) and deubiquitinated by ubiquitin‐specific peptidase 9, X‐linked (USP9X). HDAC6 promotes GS deacetylation, while USP9X removes its K48‐linked polyubiquitination, enhancing GS stability.
Go Woon Kim   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy